“Ceaselessly Securing Manufacturing Technologies”

The Radiopharmaceutical industry is clearly distinguished from other pharmaceutical businesses, particularly in terms of manufacturing technology. Highly efficient and reproducible processes are the key to success to overcome the short ‘active’ half-life (minutes to a few hours only) of most radio-tracers.
Despite its short history and yet small-scale stage, the Radiopharmaceutical industry in Korea is expected to grow rapidly employing targeted molecular compounds with differentiated radioactive isotopes for better diagnosis and more effective treatments

“Differentiated Biotech Company”

DCB was a late comer, but now is the leader in Korea’s Radiopharmaceutical market. In 2019, two first-in-class and one best-in-class radio-tracers are ongoing regulatory approval process, and an additional best-in-class Radiopharmaceutical is ready to enter clinical trials, all of which are promising a significant increase in domestic as well as international sales. We invite you to witness our growth as a successful biotech company founded on innovative Radiopharmaceuticals and advanced technologies.

Jong-Woo Kim, CEO of DuChemBio Co., Ltd.